Daxor Corporation · NASDAQ:DXR
Daxor — Investor Presentation (September 2024)
40 slides from Daxor's investor presentation, September 2024
Slide 1: Corporate Presentation September 2024
Corporate Presentation September 2024 Nasdaq: DXR
Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channe
Slide 3: Daxor Moves From AMEX to NASDAQ on February 4, 2022
Daxor Moves From AMEX to NASDAQ on February 4, 2022 COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 4: Daxor is the global leader in blood volume measurement technology
owns and operates a 20,000 SF Daxor is the global leader in blood volume state-of-the-art production and R&D facility in Oak Ridge, TN measurement technology focused on blood volume testing innovation. COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 5: Optimal Blood Volume Management Is Key to Improving Outcomes
Optimal Blood Volume Management Is Key to Improving Outcomes ~130M Patients U.S. Healthcare Burden Heart Failure $30+ Billion Hypertension $48.6+ Billion Critical Care $121-263 Billion COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 6: Managing Volume Derangement is a Challenge for Both Inpatient & Outpatient Care
Managing Volume Derangement is a Challenge for Both Inpatient & Outpatient Care The Goal: Get the Patient to Their Optimal Blood Volume & Don’t Over Treat Risks of Hypovolemia: Risks of Hypervolemia: • Tissue Hypoperfusion • Heart Failure Decompensation • Acute Kidney Injury • Accelerated Disease •
Slide 7: The Heated Debate at Bedside
“Should we try another treatment strategy?” The Heated Debate at Bedside Her hematocrit is very low. But she’s I think we need to find I think he’s still a bit wet, been getting lots of fluids. It’s not true another treatment he needs to be diuresed. anemia, it’s dilutional. strategy. COPYRIGHT © 20
Slide 8: Optimal Blood Volume is Central to Effective Heart Failure Management
Optimal Blood Volume is Central to Effective Heart Failure Management Other Volume Diagnostics are Inaccurate, Costly, and Invasive – Often Leading to Inferior Outcomes Single Single BVA Blood BVA-100 BlooTest COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 9: 98% Accurate: Leader in the New Measure of Care
Leader in the New Measure of Care Over 65,000+ Tests Performed Results FDA-Cleared Achievable Within 1 Hour 98% Accurate Inpatient Administered Direct Measurement at Point of + Care of Total Blood Volume, Outpatient Plasma, & Red Cell Volume Over 160+ Peer- Reviewed Studies Confirming Blood Volume S
Slide 10: Who We Are
DAXOR BVA-100 WHO WE ARE
Slide 11: History of Innovation
History of Innovation INCREASING EVIDENCE GROWING TRACTION First RCT demonstrates Strong YoY revenue RESEARCH mortality benefit in ICU growth & adoption at new (Yu 2011) hospital systems Volume derangement shown clinically meaningful Heterogeneity of HF proven, highlighting need FDA submission under
Slide 12: Executive Summary: 2023-2024, Unaudited
Executive Summary: 2023-2024, Unaudited COMMERCIAL CLINICAL NEW PRODUCTS • Over 100% Volumex unit growth for • New data from Baptist Heart Health • 510(k) for next-gen POC test with results 1H2024 vs. 1H2023 validating the benefits of BVA in LVAD in ~15 minutes under FDA review patient survival • Im
Slide 13: What We Do
DAXOR BVA-100 WHAT WE DO
Slide 14: Mission and Vision
Mission Advance healthcare by enabling optimal fluid management with blood volume analysis. Vision Optimal blood volume for all. COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 15: Over 65,000+ Tests Performed to Evaluate Blood Volume
Over 65,000+ Tests Performed to Evaluate Blood Volume COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 16: ezBVA Lab Service – No Capital Investment or Lab Work
ezBVA Lab Service – No Capital Investment or Lab Work Daxor’s state-of-the-art CLIA certified facility provides on-demand, next day blood volume analysis results. COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 17: Innovation & Next Generation Products
DAXOR BVA-100 INNOVATION & NEXT GENERATION PRODUCTS
Slide 18: Recipient of ~$7 Million in Government Grants & Contracts
Recipient of ~$7 Million in Government Grants & Contracts For Next Generation Systems Simpler, faster, portable blood volume analyzer for both military and civilian use under FDA review. Novel patent-pending fluorescent tracer development. BVA integration into Electronic Health Records. June 2023 Se
Slide 19: Recipient of $1.5M Grants and Matching Funds From NIH
Recipient of $1.5M Grants and Matching Funds From NIH Driving Clinical Validation and Technology Development NHLBI and NIGMS grants to develop & validate clinical decision support tools for fluid management in heart failure, sepsis, and support the development of next generation devices. COPYRIGHT ©
Slide 20: Clinical Validation
DAXOR BVA-100 CLINICAL VALIDATION
Slide 21: Making a Difference in Multiple Medical Conditions
Making a Difference in Multiple Medical Conditions Patients With Critical Blood Volume Derangements in the U.S. Annually • Heart Failure: 6+M patients, 11M deaths, 1M annual hospitalizations • Critical Care/Sepsis: 8+M admissions annually • Broadening focus indications include combat casualty care,
Slide 22: Study Shows BVA Significantly Improves Heart Failure Treatment
Study Shows BVA Significantly Improves Heart Failure Treatment *JACC-HF, 2018;11:940-948 COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 23: BVA On Admission Results in 2.6 Days Reduction in Length of Stay
BVA On Admission Results in 2.6 Days Reduction in Length of Stay Average LOS = 2.0 Days Average LOS = 4.6 Days 57% Reduction in BVA Group Length of Stay Control Group Substantial Savings for Provider Hospitals National Average Days 0 1 2 3 4 5 6 7 6.5 Days Analysis of 71 Hospitalized Heat Failure Pa
Slide 24: BVA Significantly Improves Patient Outcomes in Critical Care
BVA Significantly Improves Multiple Measures of Patient Outcomes in Critical Care “Every clinician understands the importance of maintaining normal blood volume, but the problem is how to measure it. The blood volume analyzer will mitigate the heated debate at the bedside.” Dr. Mihae Yu †M. Yu, K. P
Slide 25: Ongoing Trials
Ongoing Trials NIH-funded observational study in First-of-it’s-kind multicenter BVA- Development of clinical decision which HemoTrack, a novel multi- 100 study in hospitalized patients support tool for precision guidance of modal, multi-local wearable device with COVID-19 or sepsis. resuscitation an
Slide 26: Published Data From Leading Institutions in Peer-Reviewed Journals
Published Data From Leading Institutions in Peer-Reviewed Journals COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 27: Business Model
DAXOR BVA-100 Business Model
Slide 28: Sales Model
Sales Model BVA-100 Analyzer Volumex Single Use Kit Price Razor/Razorblade Model $460 + S&H • Sale & lease of BVA-100 Acquisition: $85,000 diagnostic systems Usage Agreement: $990 • Recurring sales of single ezBVA Lab Service use test kits • Multi-million-dollar $965 contract awards & grants COPYRIG
Slide 29: National Hospital Medicare Payment Rate
National Hospital Medicare Payment Rate* – Private Payer Rates Even Higher 78111 78121 A9524 $1,867.92 $1,352.93 $514.99 Bundled *National Payment Rate Disclaimer: The signing parties agree that Customer is purchasing laboratory nuclear medicine services and/or products "under arrangement" from Daxo
Slide 30: Excellent Value in Healthcare with Reimbursement
Excellent Value in Healthcare with Reimbursement Blood Volume-Guided Treatment Extremely Cost-Effective‡ Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF Well above 0.227 previously reported§ Far below the threshold of $50,000 ‡ Strobeck JE, Feldschuh J, Wil
Slide 31: Large, Sustainable, Serviceable Markets at Moderate Penetration Rates
Large, Sustainable, Serviceable Markets at Moderate Penetration Rates Addressable Market – Annual Recurring Revenue $2.3B Heart Failure $2,500 ~6M patients, 30% penetration $2,695 = 1.8M tests $2,000 $3.1B Critical Care, Sepsis $1,463 $1,500 ~8M patients, 20% penetration = 1.6M tests $1,000 $683 $61
Slide 32: Commercialization Channels
Commercialization Channels • Direct sales to major medical centers, hospitals & clinics for both inpatient & outpatient settings • Sales & clinical support team of 12 • International expansion with ISO 13485 certification • Military contract awards • Partnerships with MedAxiom, an ACC Company, Heart
Slide 33: Patent, Research & Development Activity
Patent, Research & Development Activity 7 5 3 433 US Patents Awarded 20,000 SF 8 Research Facility Equipped with New Patents Filed New Patents State-of-the-Art Level 2023 Anticipated for 2024 4 Clean Rooms Patents Pending Plus, numerous international patents (Europe, Japan, Canada, and the World (vi
Slide 34: BVA Value Impact – the Quadruple Aim and More
BVA Value Impact – the Quadruple Aim and More Prevent Hospital Readmissions Improve Quality Metrics Individualize Treatment to Optimize Outcomes Reduce Length of Stay Inform Fluid Management Early Improve Mortality Save Hospital Resources COPYRIGHT © 2024 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 35: Managing for Growth
Managing for Growth Acquiring Volumex® and Institutionalizing adoption Advancing diagnostic & Strong R&D Megatope® from supplier with usage protocols & therapeutic strategic with next generation device treatment guidance along with Glofil® to set to launch alliances enhance existing suite of diagnos
Slide 36: Key Metrics
Key Metrics 1940 Act Reporting Company | Publicly Traded Since 1971 Stock Symbol: DXR Exchange: Nasdaq Recent Price: $9.45 (a/o 08/16/2024) 52 Week Range: $7.11 to $10.04 Market Cap: $45.7M (a/o 08/16/2024) Shares Outstanding: 4.84M Free Float: 2.1M Insider Ownership: 56.8% Net Assets: $32.7 (a/o 06
Slide 37: Highlights
Highlights Submitted next-generation blood volume analyzer – Daxor BVA – to Appointed Dr. John L. Jefferies as Chief Medical Officer the FDA via the 510(k)/CLIA dual submission pathway Over 65,000+ tests performed with 160+ peer-reviewed published Broad and deep IP portfolio with patented technology
Slide 38: Senior Leadership
Senior Leadership Michael Feldschuh Jonathan Feldschuh John L. Jefferies, Robert Michel, President & Chief Scientific Officer Chief Executive Officer MD, MBA, MPH, CPA, MBA Harvard University Chief Financial Officer Columbia University FACC, FAHA, FAAP, Villanova University FHFSA, FESC, FRCPE St Joh
Slide 39: Key Contacts
Key Contacts Investor Relations Transfer Agent Bret Shapiro Continental Stock Transfer CORE IR 1 State Street, 30 Floor, NY, NY 10004 377 Oak Street, Garden City, NY 11530 212-509-4000 | cstmail@continentalstock.com 516-222-2560 | brets@coreir.com www.continentalstock.com www.coreir.com Corporate Co
Slide 40: Daxor.com contact details
107 Meco Lane, Oak Ridge, TN 37830 865-425-0555 | info@daxor.com Daxor.com